Open Accessibility Menu

MFA Upcoming Closures: In addition to MLK Day (January 18) and Inauguration Day (January 20), all GW Medical Faculty Associates offices located in Washington, DC only will be closed on January 19.  Click here to learn more.

Our Services

Innovative & Personalized Cancer Treatments

A highly experienced team of physicians, nurses, social workers and technologists collaborate to ensure your best possible care at the Katzen Cancer Research Center. Dedicated to the detection and treatment of patients with cancer, blood disorders and bone marrow disease, the Katzen Center provides the following services:

  • Comprehensive management of all oncologic disorders – Outpatient chemotherapy and intravenous antibiotic therapy are offered. Patients with acute oncologic problems, including acute leukemia and complex neoplastic disorders, are treated with specialized cancer treatment protocols.
  • Clinical coagulation services – Evaluation and treatment of patients with problems such as von Willebrand disease, platelet disorders, and thrombotic disorders.
  • Hematology services – Hematology services are offered for the management of patients with red cell, white cell or platelet disorders. Hemoglobinopathies, myeloproliferative diseases, and myelodysplasia are also treated.
  • The Bone Marrow Transplantation Unit –The unit performs autologous transplants on patients with leukemia, lymphomas and myelomas.

For more information about patient services, click here.

  • Ruth Paul Cancer Genetics & Prevention Service
    We offer comprehensive genetic testing and evaluation for patients who have a personal history of cancer as well as those who are at high risk for developing cancer because of a known genetic mutation and/or a strong family history of cancer. Click here to learn more.

Conveniently Located
News & Information
  • Robert Siegel, MD, to Serve as Interim Head of Medical Oncology at the GW MFA

    Robert Siegel, MD ’77, associate center director for education and training at the GW Cancer Center, professor of medicine, and former director of The Katzen Cancer Research Center, has been ...

    Read Full Article

Clinical Trials

  • Comparing Group Approaches to Improve Insomnia Symptoms Among Breast Cancer Survivors
    We are inviting women diagnosed with stage I-III breast cancer who have completed active treatment (e.g. surgery, chemotherapy, radiation) to participate in this research study. Through this study we will examine if our mind and body programs improve some of the long term effects of breast cancer treatment such as insomnia. This is a pilot phase of the study. This means that we are interested in feasibility of the program and will ask for your feedback about things you like and do not like about the program.
  • Combination immunotherapy with Herceptin and theHER2 vaccine E75 in low and intermediate HER2-expressing breast cancer patients to prevent recurrence
    This is a randomized trial for after all neo or adjuvant therapy is complete for women are Her2 1+ or HER2 2+
  • A Randomized Phase III Trial of Palbociclib with Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+)/ Human Epidermal Growth Factor Receptor 2 (HER2)-Negative early Breast Cancer (PALLAS Study)
    The purpose of the PALLAS study is to determine whether the addition of palbociclib to adjuvant endocrine therapy will improve outcomes over endocrine therapy alone for HR+/HER2- early breast cancer.
  • A Phase 3 Randomized Study Comparing Perioperative Nivolumab vs. Observation in Patients with Localized Renal Cell Carcinoma Undergoing Nephrectomy (PROSPER RCC)
    Patients who are diagnosed with RCC will be randomized to the study drug Nivolumab or Observation prior to their scheduled nephrectomy. If randomized to Nivolumab, patients will receive 1 dose prior to surgery and 6 doses after. Patients randomized to observation will proceed straight to surgery and will be monitored by observation afterward.
  • A Open-Label, Multicenter, Phase IIIb Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination with Letrozole for The Treatment of men and Pre/Postmenopausal Women With Hormone Receptor-Positive (HR+) HER-Negative (HER2-) Advanced Breast Cancer (aBC) with No Prior Hormonal Therapy for Advanced Disease
    The purpose of the PALLAS study is to determine whether the addition of palbociclib to adjuvant endocrine therapy will improve outcomes over endocrine therapy alone for HR+/HER2- early breast cancer.
  • A Global, Prospective, Non-Interventional, Observational Study of Presentation, Treatment Patterns, and Outcomes in Multiple Myeloma Patients-the INSIGHT-MM study
    The objective of this study is to describe contemporary, real-world patterns of patient characteristics, clinical disease presentation, therapeutic regimen chosen, and clinical outcomes in patients with newly diagnosed multiple myeloma and patients with relapsed/refractory multiple myeloma.